Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma.
Changjun YangFaying YangXiang ChenYunpeng LiXiaoyi HuJianming GuoJiaxi YaoPublished in: The International journal of biological markers (2023)
Our findings indicate that elevated C5a expression is associated with poor outcomes in patients with mRCC, and this effect may be partly attributed to the ability of C5a to promote EMT and PD-1/PD-L1 expression. C5a may be a potential novel target for the treatment of mRCC.